EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study — Massimo Filippi (2022) | RDL Network
EE43 Subcutaneous or Intravascular Route of Administration for Natalizumab in Relapsing Remitting Multiple Sclerosis: Economic Appraisal of the Easier Study
Massimo Filippi, Luigi Grimaldi, Antonella Conte, Rocco Totaro, Maria Rosaria Valente, Simona Malucchi, Franco Granella, Cinzia Cordioli, Vincenzo Brescia Morra, Chiara Zanetta, Daria Perini, Laura Santoni, Vanessa Ziccone, R. Garba, A. Motta, S. Albanesi, O. Oddo, A. Impagliato, Gina Ferrazzano, V. Di Rosa, Maria Carmela Tartaglia, Anna Di Vito, Alfredo R. Galassi, Roberto Prota, Roberto Garbo, Ilaria Del Negro, L. Nesi, Marco Capobianco, Elena Tsantes, R. Agosta, A. M. Valleri, L. Galuppini, Santa Mascara, F. Bertocchi, Emanuela Chiarini, Marcello Moccia, Giorgia Puorro
Helmut Butzkueven, Stephanie Licata, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Sourav Santra, Nolan Campbell, Pei‐Ran Ho
Paolo Preziosa, Maria A. Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Massimiliano Copetti, Lucia Moiola, Francesco Mele, Andrea Falini, Giancarlo Comi, Massimo Filippi
Discussion(0)
No comments yet. Be the first to comment.